<DOC>
	<DOCNO>NCT00255528</DOCNO>
	<brief_summary>This 4-week , multicenter , double-blind , placebo-controlled , randomize , parallel-group study determine antihypertensive dose range , efficacy , safety tolerability TOPROL-XL ® ( metoprolol succinate ) extended-release tablet ( metoprolol CR/XL ) hypertensive pediatric subject . The study population include school age child ( age 6 &lt; Tanner Stage 3 ) adolescent ( &gt; Tanner Stage 3 age 16 ) gender . No 50 % randomized subject could adolescent ( &gt; Tanner Stage 3 16 year old ) . Since response therapy adult hypertension appear different black non-black population , recruitment aim mixture black non-black child . The design include 1-week screening period ( treatment naive subject ) , 1-week single-blind placebo run-in period , 4-week double-blind treatment period . Eligible subject randomize double-blind period daily oral dose metoprolol CR/XL one three target dos : 0.2 , 1.0 2.0 mg/kg , placebo . Dosing weight adjust . The dose range study 12.5 200 mg daily . Subjects closely monitor evaluated end Weeks 1 , 2 , 3 4 double-blind treatment period .</brief_summary>
	<brief_title>Dose Ranging , Safety Tolerability TOPROL-XL® Extended-Release Tablets Hypertensive Pediatric Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<criteria>Male female age 6 16 year inclusive time screen . Have negative urine pregnancy test , female childbearing potential . Have sign inform consent parent legal guardian assent form sign subject ( applicable ) . Have hypertension either : 1 . Newly diagnose untreated mean sit SBP DBP 95 th percentile three consecutive office visit , 2 . Previously diagnose currently treat antihypertensive therapy Visit 1 , Visit 3 ( treatment ) mean sit SBP DBP 95 th percentile . Have ability swallow tablet . Have secondary hypertension due coarctation aorta , pheochromocytoma , hyperthyroidism Cushing ’ syndrome . Have SBP DBP great 20 ( SBP ) 10 ( DBP ) mm Hg 95th percentile use height adjust chart age gender . Have heart rate &lt; 55 beat per minute randomization . Have history asthma and/or recur pulmonary disease infection . Have history cystic fibrosis . Have know hypersensitivity reaction betablockers . Have know bleeding , coagulation platelet disorder interfere blood sampling . Have history Insulin Dependent Diabetes Mellitus . Be situation condition , opinion investigator sponsor , may interfere participation study produce significant risk subject interfere assessment safety efficacy endpoint . Have receive investigational agent therapeutic reason within 30 day prior receive study medication . Have clinically significant cardiac valvular disease . Have diagnosis heart failure . Have clinically significant arrhythmia . This define arrhythmia require medical therapy cause symptom . Atrioventricular ( AV ) conduction disturbance , ie , second third degree AV block . Be unable unwilling comply study requirement . Be noncompliant singleblind placebo runin period study define miss three dos study visit . Have impair liver function define either acute liver disease chronic liver disease persistent liver enzyme value great one one half time upper limit normal range AST ALT . Have know history bilateral renal artery stenosis , unilateral renal artery stenosis single kidney . Nephrotic subject remission exclude . Be pregnant breastfeeding infant . Currently take medication know inhibit CYP2D6 , quinidine , fluoxetine , paroxetine propafenone . Currently take catecholaminedepleting medication reserpine . For subject currently take medication know inhibit CYP2D6 catecholaminedepleting medication , sponsor must contact assess feasibility inclusion study . Currently take selective serotonin reuptake inhibitor ( SSRIs ) atypical antipsychotic medication . Have history alcohol drug abuse , positive urine screen drug abuse alcohol .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>Pediatric hypertension</keyword>
</DOC>